No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to the Indian domestic market, though the firm also distributes its offerings internationally. The company's product portfolio includes active pharmaceutical ingredients (APIs) for veterinary applications and other uses, as well as anthelmintic drugs, ingredients for animal feed, and specialized reagents employed in therapeutic treatments.
lasalabs.comNo one on the platform currently holds LASA.NS.
No tracked institution reports a position in LASA.NS as of their last filing.
No one on the platform has traded LASA.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -82.4% | -34.1% | ||||
| Profit Margin % | -135.6% | -40.1% | -18.8% | |||
| Free Cash Flow Margin % | 0.0% | -1.3% | 3.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $2.2B | +0.0% | $5.15 | $5.15–$5.15 | — | 1 |
| 2028 | $2.5B | +12.3% | $6.49 | $6.49–$6.49 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-25 | $1.32 | $-0.83 | -162.9% |
| 2026-02-11 | $1.32 | $-0.51 | -138.6% |
| 2025-08-13 | $1.32 | $-4.22 | -419.7% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| LASA.NSLasa Supergenerics Limited | $6.20 | +0.00% | $311M | — |
| BACPHAR.BOBacil Pharma Limited | $20.98 | +3.15% | $301M | — |
| BALAXI.NSBalaxi Pharmaceuticals Limited | $23.25 | +0.56% | $1.3B | — |
| BIOFILCHEM.BOBiofil Chemicals and Pharmaceuticals Limited | $33.06 | -2.02% | $539M | — |
| BIOFILCHEM.NSBiofil Chemicals and Pharmaceuticals Limited |
| $33.39 |
| -0.77% |
| $543M |
| — |
| CHOKSI.BOChoksi Asia Limited | $219.20 | -0.79% | $1.2B | — |
| MEDICAPQ.BOMedi-Caps Limited | $26.72 | -6.51% | $333M | — |
Source: Financial Modeling Prep · peers by sector/industry